Key facts
- ImmunOs Therapeutics’s last known valuation is $18.2M.
- It has raised $104.5M; the latest was Later Stage VC ($11.5M) in Aug 2024.
- Notable investors include Lightspeed Venture Partners, Redalpine, Samsara BioCapital, Mission BioCapital, Pfizer Ventures — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for ImmunOs Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for ImmunOs Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ImmunOs Therapeutics
Developer of novel human immunomodulatory proteins and drugs designed to treat cancer and autoimmune diseases. The company's drugs use proteins that have direct anti-tumour effects that remodel the tumour microenvironment and develop antibodies to block the activation of specific HLA molecules associated with autoimmune diseases, enabling healthcare providers to get biological therapeutics.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2014
- Employees
- 5
- Website
- immunostherapeutics.com/
- Ownership
- Privately Held (backing)
ImmunOs Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmunOs Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmunOs Therapeutics in its N-PORT filings yet. We sweep new filings monthly.